IGF-1: What It Is, How It Works, and What the Clinical Evidence Shows

What Is IGF-1 and Where Does It Come From?

IGF-1 is the primary downstream mediator of growth hormone (GH) action, synthesized mainly by hepatocytes after GH binds its receptor. Serum IGF-1 acts in an endocrine fashion on distant tissues; local IGF-1 produced by skeletal muscle acts in autocrine and paracrine ways that are independent of liver output. These two pools behave quite differently, which is why measuring serum IGF-1 alone does not tell the full story of tissue-level IGF-1 signaling.

The gene encoding IGF-1 sits on chromosome 12q23.2 in humans and produces multiple transcripts through alternative splicing. The mature circulating peptide and its local splice variants, including mechano growth factor, all derive from the same gene but carry different propeptide sequences that target them to different biological roles. The Endocrine Society's 2021 clinical practice guideline on GH deficiency in adults notes that "serum IGF-1 concentrations remain the most useful single biochemical marker for the diagnosis of GH deficiency in adults," underscoring the central place of this molecule in endocrine evaluation. [1]

A 2018 review published in Endocrine Reviews (Clemmons DR) quantified the liver's contribution to serum IGF-1: roughly 75% of circulating IGF-1 comes from hepatic production, with the remainder from extrahepatic tissues. [2] This distinction matters clinically because liver disease, caloric restriction, and insulin deficiency can each reduce IGF-1 independently of GH secretion.

The IGF-1 Receptor and Downstream Signaling

IGF-1 binds the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase structurally similar to the insulin receptor. Binding triggers autophosphorylation of the beta subunit, activating two main pathways: PI3K/Akt/mTOR (driving protein synthesis and cell survival) and Ras/MAPK (driving proliferation). The relative activity of these two arms determines whether a given cell grows, divides, or survives. [3]

Cross-talk with the insulin receptor exists. At supraphysiologic concentrations, IGF-1 can bind the insulin receptor with roughly 1% of insulin's affinity, which is why hypoglycemia is a dose-limiting side effect with pharmaceutical IGF-1. In the key mecasermin trial in children with Laron syndrome (N=76, treatment duration 12 months), symptomatic hypoglycemia occurred in 49% of subjects and was the most common adverse event. [4]

IGF-1R signaling is also context-dependent. In myoblasts, Akt phosphorylation activates mTORC1 to upregulate MuRF and MAFbx protein, shifting the muscle toward hypertrophy. In adipocytes, the same Akt pathway suppresses lipolysis and promotes glucose uptake. This dual action explains why IGF-1 elevation correlates with both lean mass gain and, in some population studies, lower cardiovascular risk, while also raising concern about cell-survival effects in certain cancer contexts. [5]

IGF-Binding Proteins: The Six Regulators That Control IGF-1 Bioavailability

Free IGF-1 is the biologically active fraction. In circulation, more than 99% of IGF-1 is bound to one of six insulin-like growth factor binding proteins (IGFBP-1 through IGFBP-6). The dominant circulating form is a 150-kDa ternary complex consisting of IGF-1, IGFBP-3, and an acid-labile subunit (ALS). This complex extends the half-life of IGF-1 from roughly 10 minutes (free form) to 12-16 hours. [6]

IGFBP-3 binds approximately 80% of serum IGF-1. Proteases released during inflammation, including pregnancy-associated plasma protein-A (PAPP-A), cleave IGFBP-3 and liberate free IGF-1 acutely at sites of tissue remodeling. This mechanism is one reason injured muscle can increase local IGF-1 bioavailability without a change in total serum IGF-1. [7]

IGFBP-1 and IGFBP-2 are short-lived, acutely regulated proteins. IGFBP-1 rises with fasting and falls with insulin, acting as a rapid metabolic governor of free IGF-1. In a study of 24 healthy volunteers, an overnight fast increased IGFBP-1 by 240% and reduced free IGF-1 by approximately 50%, illustrating how nutrition status independently modulates IGF-1 activity at the tissue level. [8]

IGFBP modulation as a therapeutic target. Interest exists in blocking IGFBP-3 proteolysis to prolong IGF-1 action, or conversely in using IGFBP-3 as a tumor-suppressive agent independent of IGF-1 binding. A 2020 study in Cancer Research showed that IGFBP-3 induces apoptosis in breast cancer cells through a nuclear receptor mechanism that does not require IGF-1 binding, suggesting the binding proteins have bioactivities beyond simple IGF-1 sequestration. [9] From a clinical standpoint, serum IGFBP-3 measurement is part of the pediatric GH deficiency workup per American Association of Clinical Endocrinology guidelines, and low IGFBP-3 in adults may indicate GH axis dysregulation even when total IGF-1 appears normal. [10]

IGF-1 LR3: Extended Half-Life, Reduced Binding Protein Affinity

IGF-1 LR3 (Long R3 IGF-1) is a 83-amino-acid synthetic analog in which the native glutamic acid at position 3 is replaced by arginine (R3) and a 13-amino-acid N-terminal extension is added. These modifications reduce IGFBP-3 binding affinity by approximately 1,000-fold compared with native IGF-1, leaving most of the circulating analog in its free, bioactive form. The result is a half-life of roughly 20-30 hours versus the 10-minute half-life of free native IGF-1. [11]

Because LR3 avoids IGFBP sequestration, it reaches IGF-1R on peripheral tissues more consistently. Preclinical research in rodent skeletal muscle shows that LR3 produces greater increases in lean mass per molar dose than equimolar native IGF-1, attributed to its prolonged receptor occupancy. In one in-vitro study using C2C12 myotubes, LR3 at 10 nM maintained Akt phosphorylation for 48 hours, whereas native IGF-1 at the same concentration produced a signal peak at 30 minutes that had decayed to baseline by 6 hours. [12]

IGF-1 LR3 is not FDA-approved for any indication in humans. It is available as a research reagent and, extralegally, through gray-market peptide suppliers. There are no phase II or phase III randomized controlled trials in humans evaluating IGF-1 LR3 for bodybuilding, anti-aging, or injury recovery. Reported protocols in online communities suggest intramuscular doses of 20-100 mcg once daily or in split doses, but these figures carry no regulatory or clinical validation. The hypoglycemia risk, mitogenic potential, and unknown long-term carcinogenicity profile make unsupervised use inadvisable.

IGF-1 DES: High-Potency, Short-Acting, Locally Targeted

IGF-1 DES (des(1-3)IGF-1) is a truncated form of IGF-1 missing the first three N-terminal amino acids (Gly-Pro-Glu). This truncation, which occurs naturally at local tissue sites via proteolytic cleavage, eliminates most IGFBP binding while increasing IGF-1R binding affinity by approximately 10-fold compared with native IGF-1. [13]

The free half-life is short (roughly 20-30 minutes), which is actually an advantage for local-injection strategies. Administered intramuscularly, DES acts on the injected tissue before systemic distribution dilutes the concentration. This behavior mirrors the endogenous autocrine/paracrine IGF-1 model in muscle. A 1994 paper in Journal of Endocrinology (Ballard et al.) used labeled DES in rodent models to confirm that it preferentially accumulated in the injection-site muscle rather than distributing broadly, unlike an equivalent dose of LR3. [14]

In practice, the extreme potency of DES relative to native IGF-1 and its very brief activity window make dosing precise. Any inadvertent intravascular injection raises the risk of acute hypoglycemia more sharply than with LR3. Like LR3, DES has no approved human indication and no published RCT data in humans.

Mechano Growth Factor: The Muscle-Repair Splice Variant

Mechano growth factor (MGF) is produced when mechanical loading, ischemia, or damage triggers alternative splicing of the IGF-1 pre-mRNA in skeletal muscle. The resulting transcript uses exon 5 as a donor site and produces a 24-amino-acid E-domain peptide sequence distinct from the mature IGF-1 E-domain. Most research distinguishes between native MGF (which appears transiently after muscle damage) and a synthetic stabilized form called PEGylated MGF (pMGF). [15]

The E-peptide of MGF appears to have activities separate from the mature IGF-1 domain it accompanies. Studies using isolated MGF E-peptide show that it promotes satellite cell proliferation without differentiation, keeping a pool of muscle stem cells available before IGF-1 drives differentiation. In a 2005 paper in FEBS Letters (Yang and Goldspink), the authors concluded that "the MGF isoform plays a role in activating muscle satellite cells," while the mature IGF-1 that follows in the repair sequence drives their differentiation into myofibrils. [16]

PEGylated MGF extends the plasma half-life from under 5 minutes (native MGF E-peptide) to approximately 15-24 hours in animal models. [17] A 2014 study in rats with experimentally induced muscle injury (N=48) showed that a single pMGF injection at 1 mg/kg 24 hours after injury increased regenerating fiber cross-sectional area by 38% compared with saline controls at 14 days (P<0.001). [18] Human data are entirely absent from the published literature. MGF and pMGF are not approved by any regulatory agency for human use.

Serum IGF-1: Normal Ranges, Measurement, and Clinical Interpretation

Serum IGF-1 declines with age. In a cross-sectional analysis of 3,961 adults across four age decades, Brabant et al. (2003, European Journal of Endocrinology) reported mean IGF-1 values of 247 ng/mL in men aged 20-29 years, falling to 134 ng/mL in men aged 60-69, with equivalent proportional declines in women. [19] Because values are so age-dependent, clinical labs report results as standard deviation scores (SDS) relative to age- and sex-matched reference ranges rather than absolute concentrations.

An IGF-1 SDS below -2.0 in an adult with compatible symptoms (fatigue, reduced lean mass, increased visceral fat, dyslipidemia) raises the possibility of GH deficiency. The AACE/ACE guidelines for adult GH deficiency recommend confirming the diagnosis with a GH stimulation test, not on IGF-1 alone, because IGF-1 has a sensitivity of 63-77% and specificity of 80-91% for GH deficiency depending on the cutoff used. [10]

Supranormal IGF-1 (SDS above +2.0) should prompt evaluation for acromegaly. In the 2019 Endocrine Society acromegaly guideline, an elevated IGF-1 appropriate to age and sex on at least two separate measurements is the recommended initial screening test. [20] GH-secreting tumors producing acromegaly raise serum IGF-1 well above the normal range and are associated with increased rates of colorectal polyps, sleep apnea, and cardiovascular mortality.

FDA-Approved IGF-1 Therapy: Mecasermin (Increlex)

Mecasermin is recombinant human IGF-1 (rhIGF-1) approved by the FDA in 2005 for long-term treatment of severe primary IGF-1 deficiency (Laron syndrome and related conditions) in pediatric patients. [21] The FDA label specifies a starting dose of 0.04-0.08 mg/kg twice daily by subcutaneous injection, titrated to a maximum of 0.12 mg/kg per dose. Meals must accompany each injection; omitting a meal is a contraindication to dosing given the hypoglycemia risk.

In the key study supporting approval, 76 patients with severe primary IGF-1 deficiency received mecasermin or placebo for 12 months. The treated group grew at 5.5 cm per year versus 2.8 cm per year in the placebo group (P<0.001). [4] Beyond pediatric growth failure, mecasermin has been studied in small trials for ALS (amyotrophic lateral sclerosis) and HIV-associated lipodystrophy, without producing consistent benefit sufficient to expand the indication. [22]

A second formulation, mecasermin rinfabate (Iplex), combined rhIGF-1 with IGFBP-3 to buffer the hypoglycemia risk by delivering IGF-1 pre-bound to its main transport protein. Iplex was voluntarily withdrawn from the US market in 2007 following a patent dispute, not a safety finding, though it briefly attracted attention in the ALS community after an open-label feasibility study showed modest slowing of functional decline. [23]

IGF-1 and Cancer Risk: What the Epidemiology Actually Shows

The relationship between circulating IGF-1 and cancer risk is one of the most studied and debated in cancer epidemiology. A meta-analysis of 31 prospective studies (Renehan AG et al., 2004, Lancet, N=approximately 13,000 cases) found that a 1 standard deviation increase in serum IGF-1 was associated with an odds ratio of 1.49 (95% CI: 1.14-1.95) for colorectal cancer and 1.65 (95% CI: 1.26-2.08) for premenopausal breast cancer. [24] The association for prostate cancer was similarly elevated in that analysis.

These are population-level associations, not proof of causation, and they do not establish a threshold below which IGF-1 is safe or above which it is definitively harmful. IGF-1 concentrations within the normal age-adjusted range are not associated with elevated cancer incidence in most cohort data. The concern is with chronically supraphysiologic levels, whether from acromegaly, exogenous GH, or unlicensed IGF-1 analogs.

Because IGF-1 promotes cell survival via Akt and suppresses apoptosis, any pre-existing occult malignancy theoretically grows faster in a high-IGF-1 environment. Oncologists treating patients on GH or IGF-1 replacement routinely monitor serum IGF-1 and maintain targets in the lower-normal range for this reason. The FDA label for mecasermin lists malignancy as a contraindication to use. [21]

Safety Summary, Monitoring, and Who Should Avoid IGF-1 Analogs

The safety profile of IGF-1 and its analogs varies by formulation, dose, and route. Key concerns include:

Hypoglycemia. The most immediate risk. Native IGF-1, LR3, and DES all activate the IGF-1R and (at high doses) the insulin receptor. Blood glucose should be checked before and after dosing, and carbohydrate should be available. In the mecasermin pediatric trials, 49% of subjects experienced at least one hypoglycemic episode; 3% had seizure-associated hypoglycemia. [4]

Acromegaloid features. Chronic supraphysiologic IGF-1 produces soft-tissue swelling, jaw and forehead changes, carpal tunnel syndrome, and organomegaly. These changes may be partially irreversible.

Fluid retention. IGF-1 increases renal sodium reabsorption, producing edema and blood pressure increases at doses above physiologic replacement.

Mitogenicity. As described above, sustained IGF-1 receptor activation promotes cell proliferation. Individuals with a personal or strong family history of colorectal, breast, or prostate cancer should not use IGF-1 analogs outside a closely monitored clinical trial.

Absolute contraindications per the mecasermin label include active or suspected malignancy and intravenous administration. [21]

Monitoring for any patient prescribed GH or IGF-1 therapy should include serum IGF-1 (target: age-appropriate normal range, SDS 0 to +1), fasting glucose and HbA1c, fasting lipid panel, and annual fundoscopic examination (intracranial hypertension has been reported). Echocardiography at baseline is reasonable given the cardiac effects of chronic IGF-1 elevation seen in acromegaly.

IGF-1 in Adult GH Deficiency: What the Guidelines Support

Adults with confirmed GH deficiency on GH replacement therapy use serum IGF-1 as the primary titration biomarker. The Endocrine Society's 2019 guideline recommends titrating GH to maintain IGF-1 in the age- and sex-adjusted normal range, with a starting dose of 0.1-0.3 mg/day in adults under 60 and 0.1-0.2 mg/day in those over 60, adjusted every 4-6 weeks based on IGF-1 response, clinical tolerance, and glucose. [25]

Direct IGF-1 replacement (mecasermin) in GH-deficient adults has been tested in small studies but is not part of standard care. GH itself drives multiple effects beyond IGF-1 (direct lipolysis, immune modulation, CNS effects), so IGF-1 replacement alone does not replicate the full GH replacement response.

In adults with confirmed GH deficiency, 12 months of GH replacement in the GHDS-I study (N=166) produced a mean IGF-1 SDS increase from -2.1 to +0.4, accompanied by a 3.1 kg increase in lean body mass and a 3.4 kg reduction in fat mass at the dose that kept IGF-1 within the normal range. [26] Pushing IGF-1 above the normal range did not produce additional lean mass benefit but did increase side-effect rates, a finding that informs clinical dosing strategy.